Inspira Acquires Advanced Liquid Biopsy Cancer Diagnostics Tech and Secures $15M Investment at $180M Valuation.

Inspira Technologies has entered a non-binding term sheet to acquire an advanced liquid biopsy diagnostics business for an all-share acquisition. The deal includes a $15 million strategic equity investment at a $180 million valuation, with $12 million allocated to fund existing respiratory and blood monitoring technologies. The acquisition will enable Inspira to enter the rapidly growing liquid biopsy market through a proprietary platform designed to isolate and characterize circulating tumor cells from standard blood samples.